Zoryve Topical Foam (Roflumilast ) for Sebhorreic dermatitis

Overview
Zoryve foam is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat people 9 years of age and older with seborrheic dermatitis. Zoryve foam is also referred to by its drug name, roflumilast foam.

Zoryve foam is used as a topical treatment for seborrheic dermatitis. Zoryve foam is a member of a class of drugs called phosphodiesterase 4 (PDE4) inhibitors and is not a topical steroid. Zoryve foam is believed to work by inhibiting PDE4, an enzyme involved in producing pro-inflammatory mediators. By blocking the activity of PDE4, the medication helps reduce dermatologic inflammation.

How do I take it?
Prescribing information states that Zoryve foam is applied once daily to affected areas of skin.

Side effects
The FDA-approved label for Zoryve foam lists common side effects including nasopharyngitis (inflammation of the nasal passageways), nausea, and headache.

No rare but serious side effects are listed for Zoryve foam. However, there is a warning about flammability, because some ingredients in Zoryve foam can ignite easily and burn quickly.

For more details about this treatment, visit:

Topical Roflumilast Foam — Arcutis Biotherapeutics
https://www.arcutis.com/pipeline/topical-roflum...

FAQ — Zoryve (Roflumilast Foam, 0.3%) — National Eczema Association
https://nationaleczema.org/faq-zoryve-roflumila...